Doxorubicin hydrochloride - CAS25316-40-9 Catalog number: BADC-00038

Doxorubicin hydrochloride - CAS25316-40-9 Catalog number: BADC-00038

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Doxorubicin is an anthracycline antibiotic with antineoplastic activity produced by the bacterium Streptomyces peucetius var. Doxorubicin is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.

ADCs Cytotoxin
Product Name
Doxorubicin hydrochloride
Catalog Number
Molecular Formula
Molecular Weight
Doxorubicin hydrochloride

Ordering Information

Catalog Number Size Price Quantity
BADC-00038 1 g $398
Doxorubicin is an anthracycline antibiotic with antineoplastic activity produced by the bacterium Streptomyces peucetius var. Doxorubicin is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.
Doxorubicin HCl
Canonical SMILES
Soluble ethanol, methanol, DMF, DMSO
Melting Point
Flash Point
Vapor Pressure
9.64E-28mmHg at 25°C
In Vitro
MTT assay in MCF7 cells showed significantly higher (p<0.0001) cytotoxicity for doxorubicin hydrochloride in SPIONs than doxorubicin hydrochloride solution (IC50 values 6.294±0.4169 and 11.316±0.1102μgmL(-1), respectively).
In Vivo
When CVA21 was combined with doxorubicin hydrochloride, synergistically enhanced cell death was observed when CVA21 was administered both simultaneously or 24 h prior to doxorubicin hydrochloride exposure. Doxorubicin hydrochloride had no effect on CVA21 replication. Through the use of an orthotopic (MDA-MB-231-luc) xenograft SCID mouse model of human breast cancer we showed that a single intravenous injection of CVA21 in combination with an intraperitoneal injection of doxorubicin hydrochloride resulted in significantly greater tumor reduction compared to either agent alone.
Clinical Trial Information
NCT NumberTitleCondition Or DiseasePhaseStart DateSponsorStatus
NCT00000626Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's DiseaseHIV InfectionsPhase 2National Institute of Allergy and Infectious Diseases (NIAID)Completed
NCT00000658A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's LymphomaLymphoma, Non-HodgkinPhase 3National Institute of Allergy and Infectious Diseases (NIAID)Completed
NCT00000681A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's SarcomaSarcoma, KaposiPhase 1National Institute of Allergy and Infectious Diseases (NIAID)Completed
NCT00000689Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved LymphomaLymphoma, Non-HodgkinPhase 1National Institute of Allergy and Infectious Diseases (NIAID)Completed
NCT00000703Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group MembersLymphoma, Non-HodgkinNational Institute of Allergy and Infectious Diseases (NIAID)Completed
ADCs Cytotoxin
Streptomyces peucetius
Orange Crystal Powder
Quality Standard
Shelf Life
≥360 days if stored properly
-20°C (International: -20°C)
Store at -20°C
Irritant; Health Hazard
Signal Word
Boiling Point
810.3°C at 760 mmHg
160 μL of Hela cells suspension (3×104 cell/mL) is dispensed into three 96-well U-bottom microplates and incubated for 24 h at 37°C in a fully humidified atmosphere of 5% CO2. In plate 1, serial dilutions of Doxorubicin (20 μL; final concentration, 0.1-2 μM) and Simvastatin (20 μL; final concentration, 0.25-2 μM) are added to a final volume of 200 μL and incubated for another 72 h. In plates 2 and 3 serial dilutions of each drug (Simvastatin or Doxorubicin, 40 μL) are added. After an incubation period of 24 h, the medium is aspirated and the cells are washed in PBS. Then, serial dilutions of other drug (40 μL) are added and supplemented with culture medium to a final volume of 200 μL, and incubated for 48 h. Doxorubicin and Simvastatin are used individually as positive controls (40 μL in each well), and the cells treated only with solvent are considered as negative controls. To evaluate cell survival, 20 μL of MTT solution (5 mg/mL in PBS) is added to each well and incubated for 3 h. Then the media is replaced with 150 μL of DMSO, and complete solubilization of formazan crystals is achieved by repeated pipetting of the solution. Absorbance is then determined at 540 nm by an ELISA plate reader. Each drug concentration is assayed in 4 or 8 wells and repeated 3 times. The cytotoxic/cytostatic effect of Doxorubicin is expressed as the relative viability (% control) and calculated. Percentage of cell survival in the negative control is assumed as 100.
1.Electrochemical Behavior and Square Wave Voltammetric Determination of Doxorubicin Hydrochloride
Younghee Hahn and Ho Young Lee. Arch Pharm Res Vol 27, No 1, 31-34, 2004
The detecting system connected to CE was a carbon disk working electrode with an applied potential of 0.95 V vs. a Ag/AgCI (3 M KCI), which measured anodic currents due to the oxidation of two phenolic hydroxyls in the aglycone of daunorubicin (Hu et aL, 2000). Meanwhile, reductive detecting system measured at -0.30 V was preferred to oxidation in which the chromatographic profile suffered severe interference from substances that result from the biological matrix (Ricciarello et aL, 1998). Electrochemical assay often offers selectivity and sensitivity due to the selective detection of electroactive species among the complex samples. The chemical structure of doxorubicin contains a electrochemically a reducible quinone moiety in the aglycone which prompted us to study its electro-chemical behavior by using mercury electrodes, followed by developing the fast and sensitive square wave voltammetric (SWV) procedure for the determination of doxorubicin hydrochloride in the present study.
2.Facile fabrication of thermally responsive Pluronic F127-based nanocapsules for controlled release of doxorubicin hydrochloride
Zhipeng Zeng & Zhiping Peng & Lei Chen & Yiwang Chen. Colloid Polym Sci (2014) 292:1521–1530
The short cross-linking reaction time led to the formation of nanocapsules with thin and low-cross-linked PL shell because the cross-linking reaction between the –NPC groups and –NH2 groups was slow. The difference of the contrast between the PL shell and the hollow core resulted in the typical empty core–shell structure which can be found in the TEM images. After reacting for 20 h, the diameter of the nanocapsules increased to about 200 nm as shown in Fig. 2b. Assuming that the size change of the inner cavity was negligible, the thickness of the PL shell can be estimated to be more than 60 nm. The denser and tighter (with high cross-linking density for long reaction time) PL shell resulted in the empty core–shell structure invisible in the TEM image even though the hollow inner cavity was still there. For the Pluronic F127/HA nanocapsules as shown in Fig. 2d, the smaller and instable nanocapsules were formed because of the slower reaction rate between –COOH groups and –NH2 groups. After reacting for 20 h, the diameter of the Pluronic F127/HA nanocapsules was determined to be about 220 nm. The size of the Pluronic F127/HA nanocapsules was larger than the Pluronic F127/PL nanocapsules because the content of HA was more than PL taken up by the nanocapsules. The average size was consistent with those determined from DLS results.
3.A Method for Evaluation of Therapeutic Dose of Doxorubicin Hydrochloride Using Breast Tumor Cell Culture MCF-7
Ya. D. Shanskij, Yu. A. Ershov*, and V. M. Pechennikov*. Bulletin of Experimental Biology and Medicine, Vol. 148, No. 3, 2009
Statistical data suggest that the use of anticancer drug does not signifi cantly increase the total survival of patient. This is largely associated with difficulties in rational regimen of drug usage. The choice of the dose of anticancer drugs is mainly empirical. This is also true for doxorubicin hydrochloride, antitumor antibiotic of the anthracycline family used for breast cancer management.
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Questions & Comments
Verification code
Send Inquiry
Verification code
Inquiry Basket